Items Tagged ‘Leukemia’

July 23, 2018

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation

By

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test. Data leading to the FDA approval was from a trial that included […]

View full entry

Tags: Acute Myeloid Leukemia, IGH1 Mutation, Leukemia, News, refractory, relapsed, Tibsovo, treatment


June 25, 2018

FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion,

By

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval was based on a multicenter, open-label clinical trial of venclexta with rituximab (VEN+R) versus bendamustine with rituximab (B+R) […]

View full entry

Tags: Chronic Lymphocytic Leukemia, Leukemia, News


March 22, 2018

Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia

By

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the treatment of chronic lymphocytic leukemia that has recurred following prior therapies. These results were recently presented at the 59th annual meeting of the American Society of Hematology (ASH). […]

View full entry

Tags: Chronic Lymphocytic Leukemia, cll Venetoclax, Leukemia, News, rituxan, rituximab


March 14, 2018

CRISPR Enhances Cancer Immunotherapy

By

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells — called T cells — and supercharging them to home in on and attack specific blood cancers, such as […]

View full entry

Tags: CAR T Cells, CRSIPR, immunotherapy, Leukemia, Multiple Myeloma, News


January 31, 2018

U.S. FDA Approves Trisenox® Injection for First Line Treatment of Acute Promyelocytic Leukemia

By

CancerConnect News: the U.S. Food and Drug Administration (FDA) has approved the use of Trisenox® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the (15;17) translocation or PML/RAR-alpha gene expression. The approval was based on a Priority Review by […]

View full entry

Tags: Acute Myeloid Leukemia, Leukemia, News


January 14, 2018

FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia

By

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). ABOUT CHRONIC MYELOGENOUS LEUKEMIA (CML) Chronic myelogenous leukemia (CML) is a rare blood cancer, which begins in the bone marrow, […]

View full entry

Tags: (Ph+), Bosulif, bosutinib, chronic myelogenous leukemia, Chronic Myeloid Leukemia, chronic phase, CML, Gleevec, Leukemia, News, Philadelphia chromosome positive


September 19, 2017

Pass it On: It’s Leukemia National Awareness Month

By

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia and 24,400 deaths in 2016. For lymphoma, the ACS estimates that 81,080 new cases and 21,270 deaths will occur in the United States in […]

View full entry

Tags: all, AML, CLL, CML, Leukemia, News


September 5, 2017

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia

By

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, AML, CD33 antigen, gemtuzumab ozogamicin, Leukemia, Mylotarg, News, Precision Cancer Medicine, targeted therapy


September 1, 2017

FDA Approves First Gene Therapy

By

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, cell-based gene therapy, Kymriah, Leukemia, News, tisagenlecleucel


September 1, 2017

FDA Approves First Gene Therapy

By

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, cell-based gene therapy, Kymriah, Leukemia, News, tisagenlecleucel


March 31, 2011

CML Patients Treated with Gleevec Have Normal Life Expectancy

By

People with chronic myeloid leukemia (CML) that is in complete remission after two years of treatment with Gleevec® (imatinib) have survival rates that are similar to those of the general population. These results were published in the Journal of the National Cancer Institute. Each year in the United States, approximately 5,000 people are diagnosed with […]

View full entry

Tags: Chronic Myeloid Leukemia, Leukemia


March 19, 2009

Leukemia Overview

By

Overview Leukemia is a cancer of the blood cells. There are many different types of leukemia, depending upon which specific blood cells are affected. Each leukemia has different disease characteristics and therefore different treatment options. Several clinical diagnostic tests are utilized in order to determine the type and extent of leukemia. In order to better […]

View full entry

Tags: Leukemia


October 1, 2008

Adult Acute Lymphoblastic Leukemia

By

Overview Adult ALL is a malignant disease or cancer of the blood characterized by the rapid uncontrolled growth of abnormal, immature white blood cells known as lymphoblasts. There are approximately 5,000 new cases of Adult ALL each year in the US with approximately 1500 deaths. There has been significant progress in treating adult ALL over […]

View full entry

Tags: Adult Acute Lymphoblastic Leukemia, Leukemia